Loading...
Many studies have demonstrated that long-term use of aspirin or of other nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a substantial reduction in colorectal cancer risk. The benefits of low-dose aspirin are less certain.
To explore this issue, researchers conducted a case-control analysis of population-based registry data from northern Denmark. The study involved 10,280 case patients with first-time colorectal cancer between 1994 and 2011 and 102,800 matched controls.
Continuous use of low-dose aspirin (75–100 mg per tablet) for ≥5 years was associated with a 27% reduction in colorectal cancer risk. Long-term use of nonaspirin NSAIDs (≥2 prescriptions annually for ≥5 years) was associated with a 36% reduction in risk. There…